Psyence Biomedical (Psyence Biomedical) Dividend Payout Ratio : 0.00 (As of Mar. 2023)

View and export this data going back to 2024. Start your Free Trial

Psyence Biomedical Definition

Psyence Biomedical's dividend payout ratio for the months ended in Mar. 2023 was 0.00.

The historical rank and industry rank for Psyence Biomedical's Dividend Payout Ratio or its related term are showing as below:

PBM's Dividend Payout Ratio is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.39
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2024-04-24), the Dividend Yield % of Psyence Biomedical is 0.00%.

Psyence Biomedical's Dividends per Share for the months ended in Mar. 2023 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Psyence Biomedical Dividend Payout Ratio Historical Data

The historical data trend for Psyence Biomedical's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Psyence Biomedical Annual Data

Trend

Mar21

Mar22

Mar23

Dividend Payout Ratio

Psyence Biomedical Semi-Annual Data
	Mar21	Mar22	Mar23
Dividend Payout Ratio	-	-	-

Competitive Comparison

For the Biotechnology subindustry, Psyence Biomedical's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Psyence Biomedical Dividend Payout Ratio Distribution

For the Biotechnology industry and Healthcare sector, Psyence Biomedical's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where Psyence Biomedical's Dividend Payout Ratio falls into.

Psyence Biomedical Dividend Payout Ratio Calculation

Dividend payout ratio measures the percentage of the company's earnings paid out as dividends.

Psyence Biomedical's Dividend Payout Ratio for the fiscal year that ended in Mar. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (A: Mar. 2023 )	/	EPS without NRI (A: Mar. 2023 )
	=	0	/	-0.245
	=	N/A

Psyence Biomedical's Dividend Payout Ratio for the quarter that ended in Mar. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Mar. 2023 )	/	EPS without NRI (Q: Mar. 2023 )
	=	0	/	-0.245
	=	N/A

Psyence Biomedical (NAS:PBM) Dividend Payout Ratio Explanation

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

Psyence Biomedical Dividend Payout Ratio Related Terms

Thank you for viewing the detailed overview of Psyence Biomedical's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Psyence Biomedical (Psyence Biomedical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Psyence Biomedical Ltd (NAS:PBM) » Definitions » Dividend Payout Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

121 Richmond Street West, Penthouse Suite 1300, Toronto, ON, CAN, M5H 2K1

Website

https://www.psyence.com

Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed ISO22000 facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.

Psyence Biomedical (Psyence Biomedical) Headlines

From GuruFocus

Thinking about buying stock in Psyence Biomedical, Micron Technology, Conservative Broadcast Media Journalism, Qualcomm, or Cibus?

By PRNewswire • 02-12-2024